ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Titan Medical Inc (PK)

Titan Medical Inc (PK) (TMDIF)

0.0327
0.00
( 0.00% )
업데이트: 09:00:00

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
0.0327
매수가
0.0321
매도가
0.04
거래량
-
0.00 일간 변동폭 0.00
0.0295 52주 범위 0.0949
market_cap
전일 종가
0.0327
개장가
-
최근 거래 시간
마지막 거래 시간
-
재정 규모
-
VWAP
-
평균 볼륨(3m)
62,518
발행 주식
44,250,086
배당수익률
-
주가수익률
0.19
주당순이익(EPS)
0.16
매출
17.63M
순이익
6.95M

Titan Medical Inc (PK) 정보

Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, and listed on the Toronto Stock Exchange (TMD) and the OTCQB in the United States (TITXF). Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robot... Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, and listed on the Toronto Stock Exchange (TMD) and the OTCQB in the United States (TITXF). Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery ("MIS"). The Company is currently developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. With the SPORT Surgical System, the Company aims to pursue a broad set of surgical indications, including general abdominal, gynecologic and urologic procedures. 더 보기

섹터
Ortho,prosth,surg Appl,suply
산업
Business Services, Nec
본부
Toronto, Ontario, Can
설립됨
2008
Titan Medical Inc (PK) is listed in the Ortho,prosth,surg Appl,suply sector of the OTC 시장 with ticker TMDIF. The last closing price for Titan Medical (PK) was US$0.03. Over the last year, Titan Medical (PK) shares have traded in a share price range of US$ 0.0295 to US$ 0.0949.

Titan Medical (PK) currently has 44,250,086 shares in issue. The market capitalisation of Titan Medical (PK) is US$1.45 million. Titan Medical (PK) has a price to earnings ratio (PE ratio) of 0.19.

TMDIF 최신 뉴스

No news to show yet.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
12-0.008961-21.50932526820.0416610.0450.0297625180.03688447CS
26-0.0073-18.250.040.050.0295523200.03751556CS
52-0.0363-52.60869565220.0690.09490.0295885420.05371867CS
156-0.1033-75.95588235290.1360.19950.02951069660.09476292CS
260-0.1033-75.95588235290.1360.19950.02951069660.09476292CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AGDXFAntioqua Gold Inc (CE)
US$ 0.02
(1,999,900.00%)
2.5k
ISUNQiSun Inc (CE)
US$ 0.0007
(69,900.00%)
19.26k
MGTIMGT Capital Investments Inc (CE)
US$ 0.0002
(19,900.00%)
35.2k
TTCFQTattooed Chef Inc (CE)
US$ 0.0002
(19,900.00%)
51.86k
ECPNEl Capitan Precious Metals Inc (CE)
US$ 0.0001
(9,900.00%)
2.25k
EGBBEarth Gen Biofuel Inc (CE)
US$ 0.000001
(-99.95%)
8k
CNVIFConavi Medical Corporation (PK)
US$ 0.0007
(-99.88%)
1.97k
SPRNSupernova Energy Inc (CE)
US$ 0.000001
(-99.67%)
2k
SCNGSC Holdings Corporation (CE)
US$ 0.000001
(-99.50%)
55k
FUNFFFansUnite Entertainment Inc (CE)
US$ 0.000001
(-99.50%)
2.4k
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(0.00%)
210.2M
HCMCHealthier Choices Management Corporation (PK)
US$ 0.000001
(0.00%)
118.66M
THBDThird Bench Inc (PK)
US$ 0.0003
(200.00%)
112.63M
QEDNQED Connect Inc (PK)
US$ 0.0005
(25.00%)
78.09M
RDARRaadr Inc (PK)
US$ 0.0007
(16.67%)
71.08M

TMDIF Discussion

게시물 보기
Frankestin Frankestin 4 주 전

this too! DATE FILED 2024-04-10
Why do it?
What a steal!
👍️0
Frankestin Frankestin 1 월 전


what a steal!
👍️0
Geo2014 Geo2014 1 월 전
CNVI
👍️0
SPORT19 SPORT19 1 월 전
What’s the new ticker ?
👍️0
Adrock Adrock 1 월 전
SUUUUUUUUUUUUUUem!
👍️0
SPORT19 SPORT19 1 월 전
In other single port robotic news RBOT did a 1 for 30 RS a number of months ago….
The RS brought it to around $5 however unlike TMDI the stock stayed stable and has continued to rise to over $8 today.

Worth watching IMO

👍️0
SPORT19 SPORT19 1 월 전
1 for 25 reverse split
👍️0
Renee Renee 1 월 전
TMDIF: effective Oct. 16,2024: Titan Medical has completed an amalgamation involving Conavi Medical Inc. Titan Medical and a wholly-owned subsidiary of the Company, 1000824255 Ontario Inc., which resulted in the reverse takeover of the Company by Conavi. Following completion of the Amalgamation, the Company has been renamed Conavi Medical Corp. Immediately prior to the closing of the Amalgamation, the Shares of the Company were consolidated on a 1-for-25 basis.

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
Adrock Adrock 2 월 전
RECOUNT RECOUNT
👍️0
Geo2014 Geo2014 2 월 전
I think voting was done on Dominion machines.
👍️0
Geo2014 Geo2014 2 월 전
Will do brutha! I lost on Verb too. Cuin2 is/was the biggest f’n hack pumper!



F him and his Blue Ocean Strategy!
👍️0
SPORT19 SPORT19 2 월 전
News out!!!!

https://ir.titanmedicalinc.com/news-events/press-releases/detail/423/titan-announces-resignations-of-directors
👍️0
Frankestin Frankestin 2 월 전
"everything must change so that everything stays the same"

👍️0
SPORT19 SPORT19 2 월 전
At least the directors got fired…..
👍️0
SPORT19 SPORT19 2 월 전
Once again Titan shareholders give management what they want….

Never worked a single time before….

Congratulations on locking in your losses people….
👍️0
SPORT19 SPORT19 2 월 전
https://ir.titanmedicalinc.com/news-events/press-releases/detail/422/titan-reports-voting-results-from-2023-annual-general-and
👍️0
Magnetics Magnetics 2 월 전
Thanks for your message Geo! I also got burned on VERB.. Please try to reach out to me again if you hear anything new. I've never been to stock twits but, maybe I should.. I thought that was where all the smart titan investors went. To Scoopsville...
👍️0
Geo2014 Geo2014 2 월 전
Mag, we may go after’em. If you have an account on StockTwits, go read through some of our latest posts. A few of us are trying to rally the troops. This is what gives us a glimmer of hope…

https://www.reuters.com/legal/judge-rules-that-jj-owes-auris-1-bln-related-2019-robot-deal-2024-09-04/
👍️0
Jbuffett Jbuffett 2 월 전
I can't believe the same folks are still hanging in to titan. If you haven't sold out... It's over... Time to move on to another company. Check out Monogram robotics. Ortho robotics is where the market is heading...
👍️0
bobbysixty bobbysixty 2 월 전
Agree with you. Worst financial mistake of a lifetime. I regret hearing about this company and will never invest in a penny again.
👍️0
Magnetics Magnetics 2 월 전
Checking in probably one last time here as I've lost over 150k on this.. worst experience of my life.. even more painful that it went on for 12 plus years of pain. I'm writing here one last time hoping that no one is voting yes on this.. and if you do you might as well vote for Kamala as well. After losing 150k + and still having all those shares that have been reverse split who knows how many times I'm left with a total of just 1,500 or so in stock.. a yes vote will bring even less. Only one getting paid will be the company directors on both side and lawyers.. please vote no and shut these scammers down! And I won't be attending the conference call because there's nothing to hear. It's been fun communicating with some of you over the years here. Big lesson learned here. And that this place is full of evil people trying to scam all day everyday
👍️0
Frankestin Frankestin 2 월 전

what a steal!
https://titanmedicalinc.com/enos/
https://titanmedicalinc.com/videos/
https://titanmedicalinc.com/technology/
https://titanmedicalinc.com/wp-content/uploads/2022/10/Titan-Medical-White-Paper-Supporting-Single-Access-RAS-FINAL.pdf 🤮
simply thieves!
👍️0
renaissance1 renaissance1 2 월 전
Can you please explain why you are recommending a no vote? I don’t think this company as it stands will be able to continue if they don’t do something. but in all honesty I haven’t read the circular yet so I don’t really have an educated opinion as of today. But I appreciate any info you are willing to provide. Thanks in advance and good luck. We may need it. Lol.
👍️0
Adrock Adrock 2 월 전
Withhold!!!
👍️0
SPORT19 SPORT19 3 월 전
VOTE NO!!!!

https://ir.titanmedicalinc.com/news-events/press-releases/detail/414/titan-announces-filing-of-the-management-information
👍️0
Pharmmoney Pharmmoney 3 월 전
What’s going on with the voting ?
👍️0
Frankestin Frankestin 3 월 전
👍️0
Adrock Adrock 3 월 전
https://www.medicaldevice-network.com/data-insights/titan-medical-gets-grant-for-method-for-ergonomic-positioning-of-robotic-surgery-input-device/
👍️0
SPORT19 SPORT19 3 월 전
No R&D……where did all those MILLIONS go since 12/31/23?????

VOTE NO!!!!!!!!
👍️0
FISH21049 FISH21049 3 월 전
Titan Medical Reports Operating and Financial Results for the Second Quarter 2024
Titan Medical Inc.
Thu, Aug 15, 2024, 11:32 AM CDT6 min read\

TORONTO, Ontario, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three and six months ended June 30, 2024.

Recent Activities in Q2 2024:

On May 29, 2024, the Company announced an amendment to the timeframe under which certain closing conditions must be met in the amalgamation agreement dated March 17, 2024 with Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc. (a wholly-owned subsidiary of Titan) (the “Amalgamation Agreement”).

On July 5, 2024, the Company announced the second amendment to the timeframe under which certain conditions must be met in the Amalgamation Agreement and announced the Company was seeking an additional extension with the Toronto Stock Exchange (“TSX”) to hold its Annual General and Special Meeting of Shareholders (the “Titan AGM”) on or before September 30, 2024.

On August 14, 2024, the Company announced the third amendment to alter certain closing conditions that must be met in the Amalgamation Agreement.

extending the Outside Date (as such term is defined in the Amalgamation Agreement) for completion of the Proposed Transaction to October 10, 2024;

extending the date by which the Concurrent Financing (as such term is defined in the Amalgamation Agreement) must be committed to September 3, 2024;

reducing the minimum aggregate size of the Concurrent Financing (as such term is defined in the Amalgamation Agreement) from $15 million to $7.5 million;

extending the date by which Conavi financial statements must be completed to August 23, 2024;

reducing the minimum net cash Titan must have at the Effective Time (as such term is defined in this Amalgamation Agreement) from US$5 million to US$2 million;

extending the targeted date by which the information circular for the Titan AGM must be mailed to shareholders to September 3, 2024;

extending the targeted date by which the Titan AGM must be held to September 30, 2024;

extending the targeted date by which the information circular for the Conavi annual general meeting must be mailed to shareholders to September 3, 2024; and

extending the targeted date by which the Conavi annual general meeting must be held to September 30, 2024.

Financial Highlights:

As of June 30, 2024, Titan had cash of $3.9 million, compared to $7.5 million as at December 31, 2023. Working capital was $3.3 million as of June 30, 2024, compared to $5.5 million as at December 31, 2023.

Research and development (“R&D”) expenses were nil for the three months ended June 30, 2024 compared to $0.4 million for the three months ended June 30, 2023. R&D expenses were recovery of $0.1 million for the six months ended June 30, 2024 compared to $0.8 million for the six months ended June 30, 2023.

In the three and six months ended June 30, 2023, the Company implemented cost-cutting measures that significantly reduced R&D expenses. In the six months ended June 30, 2024, R&D expense recovery of $0.1 million is attributed to cancellation of stock options and restricted share units related to R&D personnel.

General and administrative (“G&A”) expenses were $1.1 million and $2.0 million for the three and six months ended June 30, 2024 compared to $4.3 million and $6.6 million for the comparative periods ended June 30, 2023. The decrease in G&A expenses in the current period is related to the cost-cutting measures implemented in Q2, 2023. In 2023, G&A expenses included severance charges of $1.4M, transaction costs of $1.5M, and increased stock-based compensation, offset by reduction in costs due to cost-cutting measures.

The Company’s interim consolidated financial statements and management discussions and analysis for the period ended June 30, 2024 are available at www.sedarplus.ca. The Company’s condensed interim consolidated financial statements have been prepared by management and reviewed by the Company’s auditors.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) is a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property while pursuing the completion of its agreed upon Transaction with Conavi Medical Inc.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: Titan evaluating new opportunities to further develop and license its intellectual property, the payment of future settlement amounts, the delivery of materials to Titan, and the completion of the merger with Conavi.

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration and other factors listed in the “Risk Factors” section of Titan’s Annual Information Form for the fiscal year ended December 31, 2023 (which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contact
Chien Huang
Chief Financial Officer
investors@titanmedicalinc.com
👍️0
SPORT19 SPORT19 3 월 전
Vote NO to reverse takeover.

Why vote yes and lock in our 99.9% loss?

👍️0
Geo2014 Geo2014 3 월 전
Upside? What upside? You realize they’ve robbed stakeholders right? They’ve spent hundreds of millions on a single-port robot and they stopped development. They pissed away their entire IP portfolio for pennies and no one even knows where the device is at this point.
👍️0
better.to.be.lucky better.to.be.lucky 4 월 전
Happy Sunday. I'm a weekend warrior that recently discovered the Investors hub community. Been following the developments with Titan Medical Inc. (TMD) licensing deals with others for near future royalties, and also the pending Conavi Medical reverse buyout / merger. As per the info I have read in the Links below, I gather that they are in talks to Delist from the TSX: TMD; OTC: TMDIF),to then move to the TSXV after the deal hopefully gets done. I believe there is good upside with the TMD company either way. Therefore, can anyone that is savvy with this type of company reverse buyout/merger restructuring terms etc., please advise if TMD will want to, or will have to Change their Trading Symbol for the transition to the TSXV ? Thanks, appreciate any thoughts and/or comments for insight on what we may potentially be able to anticipate.

https://ih.advfn.com/stock-market/USOTC/vivos-qb-RDGL/stock-news/94191743/form-1-a-a-offering-statement-regulation-a-a
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:d031aa10-2849-4915-827d-efa78f75b532
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:a181e427-d506-468b-8fbf-093ff89ad5a6


👍️0
Frankestin Frankestin 4 월 전

APPLICATION NO 18/561705
DATE FILED 2022-05-26


what a steal!
👍️0
Adrock Adrock 5 월 전
CATAcock!!!!!
👍️0
Frankestin Frankestin 5 월 전

what a steal!
👍️0
Adrock Adrock 5 월 전
https://www.linkedin.com/posts/nickisuttoncdp_titan-medical-enos-next-generation-technology-activity-7205992450815836160-cPhl?utm_source=share&utm_medium=member_ios
👍️0
SPORT19 SPORT19 5 월 전
Link?
👍️0
Geo2014 Geo2014 5 월 전
CDP is promoting ENOS on LinkedIn. WTF???????
👍️0
SPORT19 SPORT19 6 월 전
NEWS OUT!!!

Doesn’t look good for the merger IMO
👍️0
SPORT19 SPORT19 6 월 전
I see the naysayers are out today…..
👍️0
Bronzo Bronzo 6 월 전
The ship sank. We are ghosts in a graveyard.
👍️0
Acehole Acehole 6 월 전
Sad. This was such a thriving message board at one time. Last one out please hit the lights.
👍️0
SPORT19 SPORT19 6 월 전
Sorry wrong board…
👍️0
SPORT19 SPORT19 6 월 전
Is the CEO still residing in the United States or has he left the country?

👍️0
livendi livendi 6 월 전
God bless and good luck people
👍️0
SPORT19 SPORT19 7 월 전
Nice close
👍️0
SPORT19 SPORT19 7 월 전
Awful
👍️0
nascrazy nascrazy 7 월 전
Have not dropped a cent in this slot for many years because just like any slot machine after you put your money in you pull the handle and say goodbye . The wilds were so called MDT deals that kept players pulling the handle but eventually it dries up and so goes the player .
👍️0
livendi livendi 7 월 전
we go from the 1st mdt deal and 3.60 and being close to starting fda process.now 4 yrs later 5 cents,awful.good luck with with the lawsuit if there is 1,God bless all and good luck 2
👍️0